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improved significantly and the use of DES were shown to be cost-effective. The
6-month total medical cost for DES and BMS were similar.
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OBJECTIVES: Payers and hospital administrators are increasingly concerned about
readmission rates in surgical patients. We sought to examine the readmission
rates and hospital costs associated with EVICEL fibrin sealant (all-human formula-
tion), versus VITAGEL fibrin sealant (with bovine thrombin), or no adjunct hemo-
stat use for patients undergoing inpatient joint replacement surgeries.METHODS:
A retrospective analysis was conducted using Premier administrative data from
over 500UShospitals. Hospitalized patients (18 years)whounderwent orthopedic
surgery and received EVICEL, VITAGEL or no hemostat during surgery between
January 1, 2009 and November 30, 2009 were identified. A 1:1 (EVICEL:VITAGEL) and
1:3 (EVICEL: no hemostat) match was conducted using surgery type and propensity
scores of receiving EVICEL, based on patient and hospital characteristics via a
logistic regression model. The outcomes included 30-day all-cause readmission
rates and total index hospital costs. Differences in readmission rates were ana-
lyzed using conditional logistic regression. A generalized linear model with log-
link/gamma distribution was used for analyzing differences in total costs.
RESULTS: A total of 316 patients were identified (158 per cohort) for the EVICEL
versus VITAGEL and 1,808 patients for EVICEL (n452) versus no hemostat
(n1,356) analysis. Patients in the VITAGEL cohort were 6.8 times more likely to be
readmitted to the hospital compared to the EVICEL cohort (12.7% vs 3.8%; OR6.81,
95%CI 1.62, 28.66). Patients in the no hemostat cohort were 1.6 timesmore likely to
be readmitted compared to the EVICEL cohort. Total index hospital cost was lower
for the EVICEL cohort ($16,704) compared to VITAGEL cohort ($18,192 p0.001) on
average. The EVICEL cohort ($17,387) had similar total costs compared to no ad-
junct hemostat ($17,389) cohort. CONCLUSIONS: Readmission presents significant
costs and has been added to hospital quality measures. In this study, EVICEL was
associated with lower readmission rates compared to VITAGEL or no adjunct he-
mostat use in inpatient joint replacement surgeries.
PMD7
DIFFERENCES IN OUTCOMES MEASURES OF DIABETES PATIENTS USING AN
INSULIN DEVICE AND A CONVENTIONAL HUMAN INSULIN VIAL/SYRINGE
Baser O1, Wang L1, Yuce H2, Xie L1, Dysinger AH1
1STATinMED Research, Ann Arbor, MI, USA, 2New York City College of
Technology-CUNY/STATinMED Research, New York, NY, USA
OBJECTIVES: To compare the main outcomes differences including clinical events,
health care utilization and costs of patients using an insulin device for diabetes versus
patients using the conventional human insulin vial/syringe.METHODS: Using a ret-
rospective analysis of health insurance claims data between the years 2003 and 2008,
we identified patients with a diagnosis of diabetes and then divided them into an
insulindevice cohort andahuman insulinvial/syringe cohort, basedon their prescrip-
tion fills. Patients’ demographics, health care visits and costs were compared using
Chi-square testing and standardized differences. The 12-month follow-up clinical
event rates, health care facility use and costs for those patients were compared. Risk
adjustment was performed using the propensity score matching method with the
ProbChoice™algorithm.RESULTS:A total of 12,400 eligible patientswere identifiedas
using insulin for diabetes: 1,236 (9.97%) received the insulin device and 11,164 (90.03%)
received the insulin vial/syringe. Compared with patients who received the conven-
tionalhuman insulinvial/syringe, patients in the insulindevice groupwere likely tobe
younger, live in the Midwest of the United States, and have type I diabetes. Although
there were no significant differences in hypoglycemic events after risk adjustment,
patients in the insulin device group had significantly fewer cases of cerebrovascular
disease (4.14% vs. 9.12% p0.0055), congestive heart failure (7.18% vs. 12.15%
p0.0267) and chronic obstructive pulmonarydisease (4.70%vs. 10.50%p0.0039), but
more cases of dyslipidemia (68.51% vs. 54.42% p0.0002). Although the outpatient
costs for office visits ($1888 vs. $1895 p0.0257) were lower for patients on the insulin
device, their prescription costs ($5489 vs. $4635 p0.0001) were higher. The overall
risk-adjusted healthcare costs did not differ ($14,231 vs. $18,096 p0.1160) between
the two groups. CONCLUSIONS: Without significant addition to the costs, insulin
administration with the device is associated with fewer clinical events.
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OBJECTIVES: There is no established effective lung cancer screening modality.
Positron Emission Tomography (PET) is helpful in lung cancer disease extent eval-
uation. The objective of our study is to evaluate the role of PET in lung cancer
screening via systematic review.METHODS: Using a strategy similar to a previous
computed tomography (CT) lung cancer screening systematic review [Black et al.
Thorax 2007;62:131–138], we searched for primary studies focusing on PET screen-
ing for lung cancer using the following keywords “(lung cancer) AND (positron
emission tomography) AND ((screen) OR (screening))” in Pubmed® on Nov 30th,
2010. Two reviewers (Chien C.R. & Wang H.N) reviewed all the identified studies
independently to find out studies compatible with our inclusion/exclusion criteria.
Further discussion with 3rd reviewer (Kao C.H.) was taken to reach conclusion
when there was any disagreement among the reviewers. Manual searching for
relevant studies was also performed from the included studies. We restricted our
analysis to non-overlapped studies published since 2000 and in English. RESULTS:
Among the identified studies (n2733), 239 studies were published before 2000,
2440 studies were excluded due to irrelevant titles and keywords, and another 34
studies were excluded after reviewing the abstracts. Full paper evaluation led to
further exclusion of 11 studies, and manual search led to inclusion of 2 additional
studies, leaving 11 studies for analysis. No studies evaluated the efficacy of primary
PET screening specific for lung cancer. Eight studies focused on primary PET
screening for cancer, and three studies reported finding in lung cancer CT screen-
ing programswith selective PET.CONCLUSIONS:The role of primary PET screening
for lung cancer remains unknown. PET has the potential to be used as a screening
modality not specific for lung cancer and as a selective modality in combination
with CT for lung cancer screening. [1] Black et al. Thorax 2007; 62:131-138
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OBJECTIVES:Thequality-adjusted life expectancy (QALE) and loss of quality-adjusted
life expectancy (loss of QALE) in patients under prolonged mechanical ventilation
(PMV) stratified by different underlying diseaseswere determined.METHODS:A sim-
ple randomsample of all 171, 635 patientswhowere performed continualmechanical
ventilation formore than21daysduring the1997-2007periods inTaiwan left us 50,481
subjects. After stratifying the patients according to specific diagnoses, we performed
latent class analysis (LCA) to categorize PMVpatientswithmultiple comorbidities into
several clustered groups. The survival functions were estimated for each group with
Kaplan-Meier method and extrapolated to 300months to obtain the life expectancies
through a semi-parametricmethod. The resultswere adjustedwith a utilitymeasure-
ment of quality of life to estimate the QALE (quality-adjusted life expectancies). Fur-
ther, we compared the age-, gender-matched reference populations to calculate the
loss of QALE.RESULTS: TheQALE of PMVpatientswith chronic renal failurewere 0.42
and 0.19 quality-adjusted life years (QALY) for consciousness clear versus unclear
states, respectively; those of patients with cancer were 0.48 and 0.22, respectively;
those of patients with Parkinson’s disease were 0.62 and 0.27, respectively; those of
patients with liver cirrhosis were 0.98 and 0.43 respectively; those of patients with
strokewere1.03and0.46 respectively; thoseofpatientswithdegenerativeneurological
diseases were 1.47and 0.64 respectively; those of patients with injuries and poisoning
were1.81 and 0.78 respectively. The LCA classified cases with multiple comorbidities
into several categories, of which therewas a consistent trend of decrease in QALE and
loss of QALE as people grow old. CONCLUSIONS: The results could hopefully reduce
thegapbetweenpatients’ familiesandhealthcareprovidersandassist theclinical and
health policy decisions.
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OBJECTIVES: Blood pressure control is a great challenge in the diabetic patient
population since the blood pressure target is lower, 130/80, as compared to
140/90 in general population. The objective of this study was to examine the rate
and the association of patient characteristics (demographic, access to health care
and clinical factors) and practice characteristics with hypertension screening,
treatment and control in diabetic population. METHODS: National Ambulatory
Medical Care Survey and the National Hospital Ambulatory Medical Care Survey
2006 were used to analyze outpatient visits made by adults18 years and older
diagnosed with diabetes. Descriptive analysis was done to find the rate and binary
logistic regression was carried out to find the predictors. Statistical significance
was set at alpha of 0.05. RESULTS: Hypertension screening, treatment and control
rate was 66.9%, 53.1% and 28.4% in diabetic patients. The odds of not getting
screenedwere visits other than primary care physician (OR7.52), with no diagnostic
tests (OR6.63), having no comorbidities (OR3.64), non obese (OR1.72) and increasing
age (OR2.03, OR2.35, OR2.72). Odds of not being treated were settings located in
south geographic region (OR1.29), provider other than primary care physician
(OR2.02), hospital setting (OR1.28), no diagnostic tests (OR1.97) and having no co
morbidities (OR1.558). Odds of not having blood pressure control were greater for
black race (OR 1.75), patients with no past visits (OR 1.79), obese (OR 1.37) and
having no co morbidities (OR 1.40). CONCLUSIONS: The study found that although
more than 50% of the diabetic patients were screened and treated, blood pressure
control was found in only one third of the population. Both the patient factors;
demographic, access to health care, clinical factors and practice characteristics
were responsible for poor quality of care (hypertension screening and treatment)
and poor outcome (blood pressure control).
Medical Device/Diagnostics – Cost Studies
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